Ascend GCTx–Ajinomoto: investment, 202305c financing round Series A incl co-investor Ajinomoto Co Inc |
2023-05-09 |
Ascend GCTx–Carlyle: investment, 202305c financing round Series A incl co-lead investor Abingworth |
2023-05-09 |
Ascend GCTx–Cathay Capital: investment, 202305c financing round Series A incl co-investor Cathay Health |
2023-05-09 |
Ascend GCTx–DCVC: investment, 202305c financing round Series A incl co-investor DCVC Bio |
2023-05-09 |
Ascend GCTx–Deerfield: investment, 202305c financing round Series A incl co-investor Deerfield Management |
2023-05-09 |
Ascend GCTx–Digitalis Ventures: investment, 202305c financing round Series A incl co-investor Digitalis Ventures |
2023-05-09 |
Ascend GCTx–Petrichor Healthcare: investment, 202305c financing round Series A incl co-lead investor Petrichor |
2023-05-09 |
Ascend GCTx–Ramarketing: public relations, 202305 service existent Ramarketing is media contact |
2023-05-09 |
Ascend GCTx–SEVERAL: investment, 202305c financing round Series A bringing total raised to $132.5m led by Abingworth + Petrichor |
2023-05-09 |
Cambridge Research Biochemicals–Biosynth: investment, 202305 acquisition of CRB by Biosynth |
2023-05-09 |
Bicycle Therapeutics–Helmholtz: Bicycle radio conjugates, 202305– collab to discovery + develop BRCs for a range of oncology targets with DKFZ |
2023-05-04 |
Evommune–SEVERAL: investment, 202304 financing round Series B $50m co-led by Arix Bioscience + EQT Life Sciences + SymBiosis |
2023-04-26 |
Clickmer Systems–APIS Assay Technologies: investment, 202204 acquisition of Clickmer Systems for single-digit €m by APIS Assay Technologies Ltd |
2023-04-25 |
Forbion–SEVERAL: investment, 202304 final close of Forbion Growth Opportunities Fund II with addit €130m bringing total fund size to hard cap €600m |
2023-04-19 |
Forbion–SEVERAL: investment, 202304 final close €750m of Forbion Ventures Fund VI |
2023-04-19 |
Bellus Health–GSK: investment, 202304–202306 acquisition US$2b in cash at US$14.75/share by GSK |
2023-04-18 |
Zetta Genomics–Apex Ventures: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Apex Ventures |
2023-04-18 |
Zetta Genomics–Nina Capital: investment, 202304 2nd seed financing round totalling £1.9m incl existing + lead investor Nina Capital |
2023-04-18 |
Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital |
2023-04-18 |
Zetta Genomics–Univ Cambridge: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Cambridge Enterprise |
2023-04-18 |
Complement Therapeutics–BioGeneration Ventures: investment, 202304 financing round Series A totalling €72m incl exising + co-investor BGV |
2023-04-17 |
Complement Therapeutics–Cambridge Innovation Capital: investment, 202304 financing round Series A totalling €72m incl new + co-investor CIC |
2023-04-17 |
Complement Therapeutics–Forbion: investment, 202304 financing round Series A totalling €72m incl exising + co-lead investor Forbion |
2023-04-17 |
Complement Therapeutics–Gimv: investment, 202304 financing round Series A totalling €72m incl new + lead investor Gimv |
2023-04-17 |
Complement Therapeutics–Hadean Ventures: investment, 202304 financing round Series A totalling €72m incl new + co-investor Hadean Ventures |
2023-04-17 |
Complement Therapeutics–Panakès Partners: investment, 202304 financing round Series A totalling €72m incl new + co-investor Panakès Partners |
2023-04-17 |
Complement Therapeutics–Seroba: investment, 202304 financing round Series A totalling €72m incl new + co-investor Seroba Life Sciences |
2023-04-17 |
Complement Therapeutics–SEVERAL: investment, 202304 financing round Series A €72m led by new investor Gimv |
2023-04-17 |
Mérieux–Oxford Nanopore: nanopore technology, 202304– collab strategic exploring nanopore sequencing for infectious disease diagnostics bioMérieux |
2023-04-14 |
Alentis Therapeutics–Schroders: investment, 202304 financing round Series C totalling $105m incl existing + co-investor Schroders Capital |
2023-04-13 |
Alentis Therapeutics–SEVERAL: investment, 202304 financing round Series C $105m led by Jeito Capital with Novo Holdings + RA Capital |
2023-04-13 |
AMSilk–Optimum Strategic Communications: public relations, 202304 service existent by Optimum |
2023-04-04 |
Biocartis–APIS Assay Technologies: molecular diagnostics, 202304– collab developm + commerc APIS Breast Cancer Subtyping assay on Idylla platform |
2023-04-04 |
Mosaic Therapeutics–Cambridge Innovation Capital: investment, 202304 financing round Series A totalling $28m incl investor CIC |
2023-04-04 |
Mosaic Therapeutics–SEVERAL: investment, 202304 financing round Series A $28m from Syncona + Cambridge Innovation Capital |
2023-04-04 |
Mosaic Therapeutics–Syncona: investment, 202304 financing round Series A totalling $28m incl investor Syncona Investment Management Ltd |
2023-04-04 |
Endpoints–Nikkei: investment, 202304 acquisition of majority share by The Financial Times |
2023-04-03 |
Novartis–Bicycle Therapeutics: Bicycle technology, 202303– strategic collab $50m upfront + $1.7b milestones for targeted radiopharmaceuticals |
2023-03-28 |
SR One–SEVERAL: investment, 202303 closing of SR One Fund II at $600m |
2023-03-27 |
Aldena Therapeutics–Medicxi: investment, 202303 Aldena emerges with $30m investment from co-founder Medicxi |
2023-03-16 |
Synthego–Arctoris: drug discovery services, 202303– collab co-marketing Arctoris is partner of new drug discovery services network of Synthego |
2023-03-16 |
Teitur Trophics–Optimum Strategic Communications: public relations, 202303 service existent by Optimum |
2023-03-14 |
UCB–Cancer Research UK: antibody cancer drugs, 202303– collab clinical development of UCB6114 + UCB4594 |
2023-03-09 |
AstraZeneca–Personalis: precision oncology, 202303– collab continuation use of NeXT Personal assay for clinical reserach + drug development |
2023-03-07 |
Antiverse–SEVERAL: investment, 202303 financing round $3m from existing + new investors |
2023-03-01 |
Five Alarm Bio–Acceleris: investment, 202302 seed financing round totalling >£500k incl angel investors with support from KPMG Acceleris |
2023-02-27 |
Five Alarm Bio–Cambridge Angels: investment, 202302 seed financing round totalling >£500k incl investor Cambridge Angels |
2023-02-27 |
Five Alarm Bio–Meltwind: investment, 202302 seed financing round totalling >£500k incl investor Meltwind |
2023-02-27 |
Five Alarm Bio–o2h: investment, 202302 seed financing round totalling >£500k incl investor o2h Ventures |
2023-02-27 |
Five Alarm Bio–SEVERAL: investment, 202302 seed financing round >£500k |
2023-02-27 |
Five Alarm Bio–SyndicateRoom: investment, 202302 seed financing round totalling >£500k incl investor SyndicateRoom |
2023-02-27 |
Five Alarm Bio–Zyme Communications: public relations, 202302 service existent by Zyme |
2023-02-27 |
eXmoor Pharma–Image Box: public relations, 202302 service existent by IB Communications |
2023-02-22 |
Imophoron–eXmoor Pharma: ADDomer vaccine platform, 202302– collab developm of scalable + commercializable manufacturing platform for ADDomer |
2023-02-22 |
Lift BioSciences–Consilium: public relations, 202302 service existent by Consilium Strategic Communications |
2023-02-16 |
Lift BioSciences–Resonac: biologics contract manufacturing, 202302– collab developm + manufacturing of N-LIfT for clinical trials by Minaris RM |
2023-02-16 |
Astrea Bioseparations–Biotage: investment, 202302– acquisition $190m in shares + $45 cash milestones of Astrea from Gamma Biosciences (KKR) |
2023-02-15 |
Biotage–KKR: investment, 202302– investment $25m tog with sale of Astrea Bioseparations by Gamma for shares resulting in 17% share in Biotage of Gamma |
2023-02-15 |
Maxion Therapeutics–BGF: investment, 202302 financing round Series A totalling £13m incl co-investor BGF |
2023-02-15 |
Maxion Therapeutics–LifeArc: investment, 202302 financing round Series A totalling £13m incl lead investor LifeArc Ventures |
2023-02-15 |
Maxion Therapeutics–Monograph Capital: investment, 202302 financing round Series A totalling £13m incl co-investor Monograph Capital |
2023-02-15 |
Maxion Therapeutics–SEVERAL: investment, 202302 financing round Series A £13m led by LifeArc Ventures |
2023-02-15 |
Cerevance–SEVERAL: investment, 202302 financing round Series B extension $51m bringing total Series B to $116m |
2023-02-13 |
Cydar–SEVERAL: investment, 202302 financing round Series A £9.3m led by Pembroke VCT + Downing Healthcare Ventures |
2023-02-13 |
Freeline Therapeutics–Ascend GCTx: investment, 202302 acquisition of Freeline Therapeutics GmbH for $25m by Ascend GCTx Ltd |
2023-02-10 |
HEL Group–Zyme Communications: public relations, 202302 service existent by Zyme |
2023-02-08 |
Evonetix–Cambridge Consultants: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Cambridge Consultants |
2023-02-07 |
Evonetix–Civilization Ventures: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Civilization Ventures |
2023-02-07 |
Evonetix–DCVC: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor DCVC |
2023-02-07 |
Evonetix–Foresite Capital: investment, 202302 financing round Series B extension totalling £20m incl existing + lead investor Foresite Capital |
2023-02-07 |
Evonetix–Molten Ventures: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Molten Ventures |
2023-02-07 |
Evonetix–Morningside: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Morningside |
2023-02-07 |
Evonetix–Providence Investment: investment, 202302 financing round Series B extension totalling £20m incl existing + co-investor Providence |
2023-02-07 |
Evonetix–SEVERAL: investment, 202302 financing round Series B extension £20m bringing total Series B to £43m |
2023-02-07 |
Sense Biodetection–Sherlock Biosciences: investment, 202302 acquisition €na of Sense Biodetection by Sherlock Biosciences |
2023-02-01 |
AstraZeneca–Capitainer: sample extraction, 202301– collab research using CapitainerCF self-sampling for clinical research with AZ R&D Gothenbur |
2023-01-30 |
DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-19 |
Blackford Analysis–Bayer: investment, 202301–202302 acquisition by Bayer |
2023-01-18 |
Vésale Bioscience–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-17 |
InstaDeep–BioNTech: investment, 202301–202307 acquisition of all remaining InstaDeep shares for £362m upfront in cash + shares plus £200m milestones |
2023-01-10 |
CinCor Pharma–AstraZeneca: investment, 202301–202302 acquisition cash tender offer upfront $1.3b ($26/share) + up to $500m CVR at $10/share |
2023-01-09 |
Delta Precision–Astrea Bioseparations: investment, 202301 acquisition of Delta Precision Ltd by Astrea |
2023-01-09 |
Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO |
2023-01-09 |
Amryt Pharma–Chiesi: investment, 202301– acquisition $1.25b upfront cash for all ADSs plus CVRs representing potential $225m consideration ANNOUNCED |
2023-01-08 |
Amolyt Pharma–Intermediate Capital Group: investment, 202301 financing round Series C totalling €130m incl co-lead investor ICG |
2023-01-06 |
Amolyt Pharma–SEVERAL: investment, 202301 financing round Series C €130m led by Sofinnova Partners + co-lead by ICG |
2023-01-06 |
Amolyt Pharma–Tekla Capital: investment, 202301 financing round Series C totalling €130m incl new + co-investor Tekla Capital Investment LLC |
2023-01-06 |
Akamis Bio–ARCH Venture: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor ARCH Venture Partners |
2023-01-05 |
Akamis Bio–Parker Institute: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Parker Institute |
2023-01-05 |
Akamis Bio–SEVERAL: credit, 202301 convertible note financing $30m co-led by ARCH Venture + Parker Institute + Westalke Village BioPartners |
2023-01-05 |
Akamis Bio–Westlake Village BioPartners: credit, 202301 convertible note financing totalling $30m incl new + co-lead investor Westlake Village BP |
2023-01-05 |
Mysthera Therapeutics–Forty51 Ventures: investment, 202308 seed financing $3.5m from Forty51 Ventures announced |
2023-01-01 |
Mysthera Therapeutics–Inflection Biosciences: PAM kinase inhibitors, 2023– license to Mysthera from Inflection |
2023-01-01 |
Stablepharma–CrowdCube: investment, 202212 two-part financing round Series A totalling £5.2m incl co-investor CrowdCube |
2022-12-23 |
Stablepharma–Hamilton Portfolio: investment, 202212 two-part financing round Series A totalling £5.2m incl co-lead investor Hamilton Portfolio |
2022-12-23 |
Stablepharma–Oval Investments: investment, 202212 two-part financing round Series A totalling £5.2m incl co-lead investor Oval Investments |
2022-12-23 |
Stablepharma–SEVERAL: investment, 202212 two-part financing round Series A £5.2m led by Hamilton Portfolio + Oval Investments |
2022-12-23 |
Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED |
2022-12-22 |
Inceptor Bio–Ori Biotech: CAGT manufacturing technology, 202212– collab early access to Ori Biotech’s fully automated CGT manufacturing platform |
2022-12-15 |
Ono Pharmaceutical–PrecisionLife: drug target discovery, 202212– collab r+d drug targets + biomarker discovery for CNS drugs |
2022-12-14 |